Download MendeleyDiscovery of Novel 2-Carbamoyl Morpholine Derivatives as Highly Potent and Orally Active Direct Renin Inhibitors.
Iijima, D., Sugama, H., Awai, N., Takahashi, Y., Togashi, Y., Takebe, T., Xie, J., Shen, J., Ke, Y., Akatsuka, H., Kawaguchi, T., Takedomi, K., Kashima, A., Nishio, M., Inui, Y., Yoneda, H., Xia, G., Iijima, T.(2022) ACS Med Chem Lett 13: 1351-1357
- PubMed: 35978678
- DOI: https://doi.org/10.1021/acsmedchemlett.2c00280
- Primary Citation of Related Structures:
7XGK, 7XGO - PubMed Abstract:
The renin-angiotensin-aldosterone system (RAAS) plays a key role in the regulation of blood pressure. Renin, the first and rate-limiting enzyme of the RAAS, is an attractive target for the treatment of hypertension and cardiovascular/renal diseases. Therefore, various direct renin inhibitors (DRIs) have been researched over recent decades; however, most exhibited poor pharmacokinetics and oral bioavailability due to the peptidomimetic or nonpeptidomimetic structures with a molecular weight (MW) of >600, and only aliskiren is approved. This study introduces a novel class of DRIs comprised of a 2-carbamoyl morpholine scaffold. These compounds have a nonpeptidomimetic structure and a MW of <500. The representative compound 26 was highly potent despite not occupying S1'-S2' sites or the opened flap region used by other DRIs and exerted a significant antihypertensive efficacy via oral administration on double transgenic mice carrying both the human angiotensinogen and the human renin genes.
Organizational Affiliation:
Sohyaku, Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 1000 Kamoshida-cho, Aoba-ku, Yokohama 227-0033, Japan.
